CAPTURE & CONTAIN ™
ON A MISSION TO PROTECT PATIENTS. DIFFERENTLY
The Capture and Contain Platform (C&C™) is based on natural 3-D polymeric network tailored to optimally adhere to the nasal mucosal surface. The polymeric network creates a physical barrier that Captures and Contains biological assaults and prevent their penetration.
The C&C™ platform can be readily adapted for a wide range of applications to protect the human body from airborne assaults like allergens, viruses and molds.
C&C Technology Advantages:
Easy to use
Non-irritant liquid spray
Optimal coverage of upper respiratory cavity
3-5h protection for each application
WE ARE CONSTANTLY EXPOSED TO AIRBORNE CONTAMINANTS
microorganisms transmitted by an airborne route may be spread via fine mist, dust, aerosols, or liquids. 90% of the contaminated air we breathe is inhaled through the nose and can cause serious health issues.
COLD AND FLU
7 MILLION MEDICAL VISITS
20 MILLION ILLNESS
10K-50K ANNUAL DEATHS
* Sourced from – Centers for Disease Control and Prevention (CDC.GOV)
20 MILLION AMERICANS DIAGNOSED
40 MILLION MISSED WORKDAYS PER YEAR
6 MILLION MEDICAL VISITS
$18 BILLION ANNUAL COSTS
Capture and Contain™ polymer network
Blocking effect in allergy in-vitro models
The effect of the C&C Platform (PL-14) in reduction the IL-8 secretion in response to allergens (P-value< 0.01)
Blocking effect in viral infection in-vitro models
The effect of the C&C Platform (PL-15 and PL-16) in protection of cells against viruses (P-value < 0.01)
* These products are still under development and not available for sale
COVID-19 is most infective in the upper respiratory system, where the cells express the highest level of ACE2 receptor. Then, in some cases, the virus is aspirated into the lungs where it may cause more serious disease, including potentially fatal pneumonia.
Blocking efficacy against SARS-CoV-2 Omicron BA.1 virus
The effect of the C&C Platform (PL-15) in protection of the cells againts SARS-CoV-2 Omicron BA.1 virus. (P-value < 0.01)
* Sourced from: doi.org/10.1016/j.cell.2020.05.042